{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005015","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.261640+00:00","generated_at":"2026-05-28T03:26:59.513478+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre Therapeutics expands SPY002 into RA; $603M cash runway into H2 2028","bullets":["Preliminary cash, cash equivalents, and marketable securities of ~$603M as of Dec 31, 2024, funding operations into H2 2028.","Phase 1 interim data for SPY002 (TL1A) expected 2Q2025; SPY003 (IL-23) Phase 1 interim data in 2H2025.","Phase 2 platform trial in UC launching mid-2025 with SPY001, SPY002, SPY003, and combinations; initial open-label data mid-2026.","SPY002 expansion into rheumatoid arthritis; Phase 2 RA trial start mid-2025 with topline results in 2026.","SPY001 Phase 1 data showed half-life >90 days, supporting quarterly to twice-annual subcutaneous dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005015","json":"https://secwatch.observer/filing/0001193125-25-005015.json","markdown":"https://secwatch.observer/filing/0001193125-25-005015.md","text":"https://secwatch.observer/filing/0001193125-25-005015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/0001193125-25-005015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:26:59.513478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-026656","ticker":"MVIS","company_name":"MICROVISION, INC.","filed_at":"2026-06-01T21:02:36+00:00","headline":"MicroVision seeks reverse stock split approval; ratio 1:5 to 1:15; annual meeting July 10, 2026","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026656","json":"https://secwatch.observer/filing/0001493152-26-026656.json","markdown":"https://secwatch.observer/filing/0001493152-26-026656.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/65770/000149315226026656/0001493152-26-026656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/65770/000149315226026656/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026649","ticker":"VDTA","company_name":"Vertical Data Inc.","filed_at":"2026-06-01T20:47:23+00:00","headline":"Vertical Data launches Vertical Edge, a direct-ownership edge data center platform","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026649","json":"https://secwatch.observer/filing/0001493152-26-026649.json","markdown":"https://secwatch.observer/filing/0001493152-26-026649.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/0001493152-26-026649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2033264/000149315226026649/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026638","ticker":"XAIR","company_name":"Beyond Air, Inc.","filed_at":"2026-06-01T20:30:41+00:00","headline":"Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026638","json":"https://secwatch.observer/filing/0001493152-26-026638.json","markdown":"https://secwatch.observer/filing/0001493152-26-026638.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/0001493152-26-026638-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641631/000149315226026638/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001467623-26-000040","ticker":"DBX","company_name":"DROPBOX, INC.","filed_at":"2026-06-01T13:06:23+00:00","headline":"Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program","event_type":"other_material","sec_items":["1.01","2.03","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001467623-26-000040","json":"https://secwatch.observer/filing/0001467623-26-000040.json","markdown":"https://secwatch.observer/filing/0001467623-26-000040.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/0001467623-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1467623/000146762326000040/dbx-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}